Groundbreaking TA-TMA Treatment Gets FDA Green Light: Omeros' Yartemlea Marks New Era in Transplant Complications

For patients facing post-transplant thrombotic microangiopathy (TA-TMA)—a devastating and frequently life-threatening condition that emerges after stem cell procedures—the therapeutic landscape has fundamentally shifted. The FDA’s approval of Omeros Corp.'s Yartemlea (narsoplimab-wuug) represents a watershed moment: it is the first and only federally approved medication specifically targeting this rare transplant-related complication.

Understanding the Breakthrough: How Yartemlea Works

TA-TMA develops when the transplanted immune system attacks the recipient’s blood vessels, triggering a cascade of clotting complications. Traditional management approaches lacked disease-specific interventions, leaving clinicians with few evidence-based options. Yartemlea operates through a novel mechanism—it selectively inhibits the lectin pathway of the complement system by targeting MASP-2, thereby halting the pathological complement activation that drives TA-TMA while maintaining the immune defenses needed for infection prevention and graft survival.

This targeted approach addresses a critical unmet need in transplant medicine, where complications like TA-TMA have historically carried grim prognosis.

Clinical Evidence: From Pivotal Data to Real-World Outcomes

The FDA’s decision rested on compelling efficacy data. In the pivotal trial involving 28 adult patients with severe disease, 61% achieved complete response to treatment. More significantly, 100-day survival reached 73%—substantially above expectations for a high-risk population with uniformly poor baseline prognosis.

Extended access data corroborated these findings. Among patients who had previously failed off-label therapeutic attempts, one-year survival climbed to 50%, a remarkable improvement compared to historical survival rates languishing below 20%. Peer-reviewed analyses documented a three- to fourfold mortality reduction versus external control cohorts.

Market Timeline and Regulatory Pathway

Omeros intends to make Yartemlea available in U.S. markets beginning in January 2026. Billing and reimbursement infrastructure is already established, positioning the company for rapid market entry. European regulatory decisions are anticipated mid-2026, signaling Yartemlea’s potential international availability shortly thereafter.

The approval encompasses adult and pediatric populations aged two years and older, broadening access across age groups affected by TA-TMA.